Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014

Noriaki Kawano, Shuro Yoshida, Sayaka Kawano, Takuro Kuriyama, Kiyoshi Yamashita, Hidenobu Ochiai, Kazuya Shimoda, Fumihiko Ishikawa, Akira Ueda, Ikuo Kikuchi

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Although clinical trials of first- and second-generation tyrosine kinase inhibitors (TKIs) have been shown to improve the prognosis of chronic myeloid leukemia (CML), there is still uncertainty about the clinical features, treatment outcomes, adverse effects, and other possible problems of their use in the clinical setting. We retrospectively analyzed 51 CML patients treated with TKIs at a single institution between 2002 and 2014. The patients (median age: 53.8 years) were classified as having chronic (n = 48), accelerated (n = 2), or blastic phase (n = 1) CML. Our treatments included both 1st generation TKIs (60.8%) and 2nd generation TKIs (39.2%). We found that the overall response rates of complete cytogenetic response (CCyR), major molecular response (MMR), and MR4 (molecular response 4) were 90.2%, 78.4%, and 64.7%, respectively. Second line 2nd generation TKIs had response rates equivalent to those of 1st line 1st generation TKIs. Moreover, 1st line 2nd generation TKIs tended to achieve an early response rate. Overall survival (OS) at 5 years was 93.2%. Sudden blastic crisis (BC) occurred in 2 CML patients receiving TKI with CCyR status. Hematopoietic stem cell transplantation was performed for BC (n = 1) and sudden BC (n = 2). Side effects of all grades (1-3) and grade 3 alone were 64.7% and 11.8%, respectively. Dose reduction, replacement with another TKI, or low dose TKI treatment may be useful methods to control side effects. Further reasons of TKI discontinuation were economic problems (n = 3) and pregnancy (n = 1). Consequently, our treatment strategy for CML demonstrated good response rate and OS. Currently, treatment discontinuation due to intolerance, resistance, economic problems, pregnancy, and sudden BC remains a concern in clinical practice.

    Original languageEnglish
    Pages (from-to)34-42
    Number of pages9
    JournalJournal of clinical and experimental hematopathology : JCEH
    Volume56
    Issue number1
    DOIs
    Publication statusPublished - Jan 1 2016

    Fingerprint

    Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    Protein-Tyrosine Kinases
    Cytogenetics
    Economics
    Pregnancy
    Hematopoietic Stem Cell Transplantation
    Therapeutics
    Uncertainty
    Survival Rate
    Clinical Trials
    Survival

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Cite this

    Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. / Kawano, Noriaki; Yoshida, Shuro; Kawano, Sayaka; Kuriyama, Takuro; Yamashita, Kiyoshi; Ochiai, Hidenobu; Shimoda, Kazuya; Ishikawa, Fumihiko; Ueda, Akira; Kikuchi, Ikuo.

    In: Journal of clinical and experimental hematopathology : JCEH, Vol. 56, No. 1, 01.01.2016, p. 34-42.

    Research output: Contribution to journalArticle

    Kawano, Noriaki ; Yoshida, Shuro ; Kawano, Sayaka ; Kuriyama, Takuro ; Yamashita, Kiyoshi ; Ochiai, Hidenobu ; Shimoda, Kazuya ; Ishikawa, Fumihiko ; Ueda, Akira ; Kikuchi, Ikuo. / Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. In: Journal of clinical and experimental hematopathology : JCEH. 2016 ; Vol. 56, No. 1. pp. 34-42.
    @article{6b85fdecc41142468bd44c15b9c865fe,
    title = "Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014",
    abstract = "Although clinical trials of first- and second-generation tyrosine kinase inhibitors (TKIs) have been shown to improve the prognosis of chronic myeloid leukemia (CML), there is still uncertainty about the clinical features, treatment outcomes, adverse effects, and other possible problems of their use in the clinical setting. We retrospectively analyzed 51 CML patients treated with TKIs at a single institution between 2002 and 2014. The patients (median age: 53.8 years) were classified as having chronic (n = 48), accelerated (n = 2), or blastic phase (n = 1) CML. Our treatments included both 1st generation TKIs (60.8{\%}) and 2nd generation TKIs (39.2{\%}). We found that the overall response rates of complete cytogenetic response (CCyR), major molecular response (MMR), and MR4 (molecular response 4) were 90.2{\%}, 78.4{\%}, and 64.7{\%}, respectively. Second line 2nd generation TKIs had response rates equivalent to those of 1st line 1st generation TKIs. Moreover, 1st line 2nd generation TKIs tended to achieve an early response rate. Overall survival (OS) at 5 years was 93.2{\%}. Sudden blastic crisis (BC) occurred in 2 CML patients receiving TKI with CCyR status. Hematopoietic stem cell transplantation was performed for BC (n = 1) and sudden BC (n = 2). Side effects of all grades (1-3) and grade 3 alone were 64.7{\%} and 11.8{\%}, respectively. Dose reduction, replacement with another TKI, or low dose TKI treatment may be useful methods to control side effects. Further reasons of TKI discontinuation were economic problems (n = 3) and pregnancy (n = 1). Consequently, our treatment strategy for CML demonstrated good response rate and OS. Currently, treatment discontinuation due to intolerance, resistance, economic problems, pregnancy, and sudden BC remains a concern in clinical practice.",
    author = "Noriaki Kawano and Shuro Yoshida and Sayaka Kawano and Takuro Kuriyama and Kiyoshi Yamashita and Hidenobu Ochiai and Kazuya Shimoda and Fumihiko Ishikawa and Akira Ueda and Ikuo Kikuchi",
    year = "2016",
    month = "1",
    day = "1",
    doi = "10.3960/jslrt.56.34",
    language = "English",
    volume = "56",
    pages = "34--42",
    journal = "Journal of clinical and experimental hematopathology : JCEH",
    issn = "1346-4280",
    publisher = "Nihon Rinpa Monaikei Gakkai",
    number = "1",

    }

    TY - JOUR

    T1 - Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014

    AU - Kawano, Noriaki

    AU - Yoshida, Shuro

    AU - Kawano, Sayaka

    AU - Kuriyama, Takuro

    AU - Yamashita, Kiyoshi

    AU - Ochiai, Hidenobu

    AU - Shimoda, Kazuya

    AU - Ishikawa, Fumihiko

    AU - Ueda, Akira

    AU - Kikuchi, Ikuo

    PY - 2016/1/1

    Y1 - 2016/1/1

    N2 - Although clinical trials of first- and second-generation tyrosine kinase inhibitors (TKIs) have been shown to improve the prognosis of chronic myeloid leukemia (CML), there is still uncertainty about the clinical features, treatment outcomes, adverse effects, and other possible problems of their use in the clinical setting. We retrospectively analyzed 51 CML patients treated with TKIs at a single institution between 2002 and 2014. The patients (median age: 53.8 years) were classified as having chronic (n = 48), accelerated (n = 2), or blastic phase (n = 1) CML. Our treatments included both 1st generation TKIs (60.8%) and 2nd generation TKIs (39.2%). We found that the overall response rates of complete cytogenetic response (CCyR), major molecular response (MMR), and MR4 (molecular response 4) were 90.2%, 78.4%, and 64.7%, respectively. Second line 2nd generation TKIs had response rates equivalent to those of 1st line 1st generation TKIs. Moreover, 1st line 2nd generation TKIs tended to achieve an early response rate. Overall survival (OS) at 5 years was 93.2%. Sudden blastic crisis (BC) occurred in 2 CML patients receiving TKI with CCyR status. Hematopoietic stem cell transplantation was performed for BC (n = 1) and sudden BC (n = 2). Side effects of all grades (1-3) and grade 3 alone were 64.7% and 11.8%, respectively. Dose reduction, replacement with another TKI, or low dose TKI treatment may be useful methods to control side effects. Further reasons of TKI discontinuation were economic problems (n = 3) and pregnancy (n = 1). Consequently, our treatment strategy for CML demonstrated good response rate and OS. Currently, treatment discontinuation due to intolerance, resistance, economic problems, pregnancy, and sudden BC remains a concern in clinical practice.

    AB - Although clinical trials of first- and second-generation tyrosine kinase inhibitors (TKIs) have been shown to improve the prognosis of chronic myeloid leukemia (CML), there is still uncertainty about the clinical features, treatment outcomes, adverse effects, and other possible problems of their use in the clinical setting. We retrospectively analyzed 51 CML patients treated with TKIs at a single institution between 2002 and 2014. The patients (median age: 53.8 years) were classified as having chronic (n = 48), accelerated (n = 2), or blastic phase (n = 1) CML. Our treatments included both 1st generation TKIs (60.8%) and 2nd generation TKIs (39.2%). We found that the overall response rates of complete cytogenetic response (CCyR), major molecular response (MMR), and MR4 (molecular response 4) were 90.2%, 78.4%, and 64.7%, respectively. Second line 2nd generation TKIs had response rates equivalent to those of 1st line 1st generation TKIs. Moreover, 1st line 2nd generation TKIs tended to achieve an early response rate. Overall survival (OS) at 5 years was 93.2%. Sudden blastic crisis (BC) occurred in 2 CML patients receiving TKI with CCyR status. Hematopoietic stem cell transplantation was performed for BC (n = 1) and sudden BC (n = 2). Side effects of all grades (1-3) and grade 3 alone were 64.7% and 11.8%, respectively. Dose reduction, replacement with another TKI, or low dose TKI treatment may be useful methods to control side effects. Further reasons of TKI discontinuation were economic problems (n = 3) and pregnancy (n = 1). Consequently, our treatment strategy for CML demonstrated good response rate and OS. Currently, treatment discontinuation due to intolerance, resistance, economic problems, pregnancy, and sudden BC remains a concern in clinical practice.

    UR - http://www.scopus.com/inward/record.url?scp=85015587730&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85015587730&partnerID=8YFLogxK

    U2 - 10.3960/jslrt.56.34

    DO - 10.3960/jslrt.56.34

    M3 - Article

    C2 - 27334856

    AN - SCOPUS:85015587730

    VL - 56

    SP - 34

    EP - 42

    JO - Journal of clinical and experimental hematopathology : JCEH

    JF - Journal of clinical and experimental hematopathology : JCEH

    SN - 1346-4280

    IS - 1

    ER -